- Home
- AENT vs GNFT Comparison
AENT vs GNFT Comparison
Compare AENT & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- GNFT
- Stock Information
- Founded
- AENT 1990
- GNFT 1999
- Country
- AENT United States
- GNFT France
- Employees
- AENT N/A
- GNFT N/A
- Industry
- AENT Durable Goods
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AENT Consumer Discretionary
- GNFT Health Care
- Exchange
- AENT Nasdaq
- GNFT Nasdaq
- Market Cap
- AENT 161.5M
- GNFT 186.3M
- IPO Year
- AENT N/A
- GNFT 2019
- Fundamental
- Price
- AENT $4.97
- GNFT $3.97
- Analyst Decision
- AENT Strong Buy
- GNFT Strong Buy
- Analyst Count
- AENT 1
- GNFT 1
- Target Price
- AENT $10.00
- GNFT $13.00
- AVG Volume (30 Days)
- AENT 42.0K
- GNFT 2.6K
- Earning Date
- AENT 09-18-2025
- GNFT 09-18-2025
- Dividend Yield
- AENT N/A
- GNFT N/A
- EPS Growth
- AENT N/A
- GNFT N/A
- EPS
- AENT 0.23
- GNFT 0.03
- Revenue
- AENT $1,072,641,000.00
- GNFT $73,187,701.00
- Revenue This Year
- AENT N/A
- GNFT $15.98
- Revenue Next Year
- AENT $0.73
- GNFT N/A
- P/E Ratio
- AENT $21.40
- GNFT $131.89
- Revenue Growth
- AENT N/A
- GNFT 105.01
- 52 Week Low
- AENT $1.10
- GNFT $2.55
- 52 Week High
- AENT $11.57
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- AENT 48.82
- GNFT 51.25
- Support Level
- AENT $5.57
- GNFT $3.94
- Resistance Level
- AENT $5.70
- GNFT $4.19
- Average True Range (ATR)
- AENT 0.59
- GNFT 0.11
- MACD
- AENT -0.15
- GNFT 0.04
- Stochastic Oscillator
- AENT 11.56
- GNFT 63.66
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.